ArticleiScience2026

RPL18 promotes melanoma progression and drug resistance via BTF3/STAT3-dependent mechanisms and immune modulation.

Chenchen Zuo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.